Kolon Life Science (XKRX:102940) Long-Term Capital Lease Obligation : ₩238 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Long-Term Capital Lease Obligation?

Kolon Life Science's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩238 Mil.

Kolon Life Science's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (₩255 Mil) to Dec. 2023 (₩191 Mil) but then increased from Dec. 2023 (₩191 Mil) to Mar. 2024 (₩238 Mil).

Kolon Life Science's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (₩191 Mil) to Dec. 2022 (₩167 Mil) but then increased from Dec. 2022 (₩167 Mil) to Dec. 2023 (₩191 Mil).

Kolon Life Science Long-Term Capital Lease Obligation Historical Data

The historical data trend for Kolon Life Science's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Long-Term Capital Lease Obligation Chart

Kolon Life Science Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

142.56

262.15

191.02

167.18

191.33

Kolon Life Science Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															222.33	321.43	254.69	191.33	238.16

Kolon Life Science (XKRX:102940) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Kolon Life Science Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon Life Science (XKRX:102940) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR

Website

http://www.kolonls.co.kr

Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines